Leonardo Lorente1, María M Martín2, Ester López-Gallardo3, José Blanquer4, Jordi Solé-Violán5, Lorenzo Labarta6, César Díaz7, Alejandro Jiménez8, Julio Montoya9, Eduardo Ruiz-Pesini10. 1. Intensive Care Unit, Hospital Universitario de Canarias, Ofra, s/n La Laguna, 38320, Santa Cruz de Tenerife, Spain. Electronic address: lorentemartin@msn.com. 2. Intensive Care Unit, Hospital Universitario Nuestra Señora Candelaria, Crta Rosario s/n Santa Cruz Tenerife, 38010, Spain. Electronic address: mar.martinvelasco@gmail.com. 3. Departamento de Bioquímica y Biología Molecular y Celular, Centro de Investigaciones Biomédicas En Red de Enfermedades Raras e Instituto de Investigación Sanitaria de Aragón, Universidad de Zaragoza, Zaragoza, 50013, Spain. Electronic address: esterlop@unizar.es. 4. Intensive Care Unit, Hospital Clínico Universitario de Valencia, Avda Blasco Ibáñez n°17-19, Valencia, 46004, Spain. Electronic address: blanquer_jos@gva.es. 5. Intensive Care Unit, Hospital Universitario Dr Negrín, Barranco de la Ballena s/n Las Palmas de Gran Canaria, 35010, Spain. Electronic address: jsolvio@gobiernodecanarias.org. 6. Intensive Care Unit, Hospital San Jorge de Huesca, Avenida Martínez de Velasco n°36 Huesca, 22004, Spain. Electronic address: llabarta@salud.aragon.es. 7. Intensive Care Unit, Hospital Insular, Plaza Dr Pasteur s/n Las Palmas de Gran Canaria, 35016, Spain. Electronic address: incaicos@yahoo.es. 8. Research Unit, Hospital Universitario de Canarias, Ofra, s/n La Laguna, 38320, Santa Cruz de Tenerife, Spain. Electronic address: ajimenezsosa@gmail.com. 9. Departamento de Bioquímica y Biología Molecular y Celular, Centro de Investigaciones Biomédicas En Red de Enfermedades Raras e Instituto de Investigación Sanitaria de Aragón, Universidad de Zaragoza, Zaragoza, 50013, Spain. Electronic address: jmontoya@unizar.es. 10. Departamento de Bioquímica y Biología Molecular y Celular, Centro de Investigaciones Biomédicas En Red de Enfermedades Raras e Instituto de Investigación Sanitaria de Aragón, Universidad de Zaragoza, Zaragoza, 50013, Spain. Electronic address: eduruiz@unizar.es.
Abstract
OBJECTIVE: The comparison of oxidative phosphorylation system capacities between septic patients and control subjects has been scarcely analyzed and only in studies with small sample size (fewer than 40 septic patients and 40 controls). Thus, the objective of this study was to compare platelet respiratory complex IV (CIV) activity between severe septic patients and healthy individuals in a larger series (including 198 severe septic patients and 96 healthy controls). METHODS: A prospective, multicenter, observational study was carried out in 6 Spanish intensive care units. We obtained blood samples from 198 severe septic patients at day 1, 4, and 8 of the severe sepsis diagnosis and 96 sex- and age-matched healthy control individuals and determined platelet CIV-specific activity. The end point of the study was 30-day mortality. RESULTS: Control individuals showed higher platelet CIV-specific activity (P < .001) than surviving (n = 130) or nonsurviving (n = 68) severe septic patients at day 1, 4, and 8 of severe sepsis diagnosis. CONCLUSIONS: The major finding of our work, involving the largest series to date of severe septic patients with data on oxidative phosphorylation system capacity, was that surviving and nonsurviving septic patients showed lower platelet CIV-specific activity during the first week of sepsis than healthy controls.
OBJECTIVE: The comparison of oxidative phosphorylation system capacities between septicpatients and control subjects has been scarcely analyzed and only in studies with small sample size (fewer than 40 septicpatients and 40 controls). Thus, the objective of this study was to compare platelet respiratory complex IV (CIV) activity between severe septicpatients and healthy individuals in a larger series (including 198 severe septicpatients and 96 healthy controls). METHODS: A prospective, multicenter, observational study was carried out in 6 Spanish intensive care units. We obtained blood samples from 198 severe septicpatients at day 1, 4, and 8 of the severe sepsis diagnosis and 96 sex- and age-matched healthy control individuals and determined platelet CIV-specific activity. The end point of the study was 30-day mortality. RESULTS: Control individuals showed higher platelet CIV-specific activity (P < .001) than surviving (n = 130) or nonsurviving (n = 68) severe septicpatients at day 1, 4, and 8 of severe sepsis diagnosis. CONCLUSIONS: The major finding of our work, involving the largest series to date of severe septicpatients with data on oxidative phosphorylation system capacity, was that surviving and nonsurviving septicpatients showed lower platelet CIV-specific activity during the first week of sepsis than healthy controls.
Authors: Michael A Puskarich; Jeffrey A Kline; John A Watts; Kristin Shirey; Jonathan Hosler; Alan E Jones Journal: J Crit Care Date: 2015-10-26 Impact factor: 3.425
Authors: David H Jang; Clinton J Orloski; Shawn Owiredu; Frances S Shofer; John C Greenwood; David M Eckmann Journal: Shock Date: 2019-05 Impact factor: 3.454
Authors: L Lorente; M M Martín; A Pérez-Cejas; A F González-Rivero; R O López; J Ferreres; J Solé-Violán; L Labarta; C Díaz; S Palmero; A Jiménez Journal: Eur J Clin Microbiol Infect Dis Date: 2017-11-08 Impact factor: 3.267
Authors: Marc R McCann; Cora E McHugh; Maggie Kirby; Theodore S Jennaro; Alan E Jones; Kathleen A Stringer; Michael A Puskarich Journal: Metabolites Date: 2020-04-02
Authors: Sebastián P Chapela; Isabel Burgos; Christian Congost; Romina Canzonieri; Alexis Muryan; Manuel Alonso; Carlos A Stella Journal: Oxid Med Cell Longev Date: 2018-11-06 Impact factor: 6.543
Authors: Sebastien Preau; Dominique Vodovar; Boris Jung; Steve Lancel; Lara Zafrani; Aurelien Flatres; Mehdi Oualha; Guillaume Voiriot; Youenn Jouan; Jeremie Joffre; Fabrice Uhel; Nicolas De Prost; Stein Silva; Eric Azabou; Peter Radermacher Journal: Ann Intensive Care Date: 2021-07-03 Impact factor: 6.925
Authors: Andrea Vernerova; Luiz Felipe Garcia-Souza; Ondrej Soucek; Milan Kostal; Vit Rehacek; Lenka Kujovska Krcmova; Erich Gnaiger; Ondrej Sobotka Journal: Biomedicines Date: 2021-12-08